Nanoscope Therapeutics
Nanoscope Therapeutics Inc. is a clinical-stage biotechnology company that is developing gene-agnostic therapies for individuals with retinal degenerative diseases. In October 2022, the company announced the FDA has granted Fast Track Designation to their asset MCO-010, an optogenetic monotherapy, that through injection can be a treatment for retinitis pigmentosa (RP). Having a Fast Track Designation is significant because it expedites the review process of a novel therapy by allowing for increased communication with the FDA regarding regulatory hurdles.
In March 2023, Nanoscope announced positive topline results from its Phase 2b RESTORE Trial of MCO-010 for the treatment of retinitis pigmentosa.
Nanoscope Therapeutics website
Clinicaltrials.gov ID NCT04945772
Nanoscope Related Science News
Nanoscope Therapeutics announced positive top-line results from a Phase 2b trial of MCO-010 for retinitis pigmentosa (RP).
Nanoscope Therapeutics Inc., a clinical-stage biotechnology company, has recently announced that one of its drugs is approved for Phase 2b clinical trial.
